Guoling Li

机构：Shanghai Institute of Materia Medica, NewGen Therapeutics (United States)

发表论文 64 篇 · 总被引 1609 次 · h-index 22

代表论文

• High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects (2022 · Nature Biotechnology · 被引 234)
• Engineered CRISPR-OsCas12f1 and RhCas12f1 with robust activities and expanded target range for genome editing (2023 · Nature Communications · 被引 96)
• Development of miniature base editors using engineered IscB nickase (2023 · Nature Methods · 被引 91)
• Programmable deaminase-free base editors for G-to-Y conversion by engineered glycosylase (2023 · National Science Review · 被引 77)
• Development of deaminase-free T-to-S base editor and C-to-G base editor by engineered human uracil DNA glycosylase (2024 · Nature Communications · 被引 51)
• Engineering a transposon-associated TnpB-ωRNA system for efficient gene editing and phenotypic correction of a tyrosinaemia mouse model (2024 · Nature Communications · 被引 44)